Argus Research Initiates Coverage On New Residential Inv with Buy Rating, Announces $18 Price Target

Argus Research analyst Kevin Heal initiates coverage on New Residential Inv (NYSE:NRZ) with a Buy rating and a $18 price target.

Benzinga · 12/31/2019 12:48

Argus Research analyst Kevin Heal initiates coverage on New Residential Inv (NYSE:NRZ) with a Buy rating and a $18 price target.